What potential emotional issues may arise following weight reduction after administration of semaglutide and tiramptide injections?
Two years ago, a study published in JAMA Network Open in 2024 analyzed the World Health Organization (WHO) Global Adverse Drug Reaction Database. The results showed that individuals using semaglutide had a 45% increased risk of suicidal ideation compared to those using other hypoglycemic agents.
More specific data indicate that among over 30,000 adverse reaction reports of semaglutide, 107 cases were associated with suicide or self-harm, accounting for 0.35%. Of these, 88% involved suicidal ideation and 6.5% involved attempted suicide. The average time from initiation of medication to the emergence of suicidal ideation was 80 days, approximately two and a half months.
Another real-world study published in Nature in 2025 revealed that women using GLP-1 agents exhibited an 119% increased risk of anxiety and a 153% elevated risk of suicidal ideation or behavior. Younger patients (aged 18 to 49) faced significantly higher risks, nearly twice those observed in elderly patients. Even among GLP-1 agents, individual emotional responses varied substantially across different populations.
Why do some people experience low mood? Three possible reasons:
The first reason is changes in nutrition and neurotransmitters. GLP-1 agents suppress appetite, leading many patients to consume less food, resulting in insufficient intake of proteins, B vitamins, and omega-3 fatty acids. These nutrients serve as precursors for the synthesis of serotonin and dopamine, and their deficiency naturally leads to low mood.
The second reason is the direct pharmacological effects on the brain. GLP-1 receptors are distributed in regions of the brain such as the nucleus accumbens and hippocampus, which are involved in emotion regulation, reward processing, and memory. Pharmacological activation of these receptors may theoretically influence emotional modulation. Studies suggest that susceptible individuals may experience anhedonia, characterized by a lack of interest in various stimuli.
The third reason is psychosocial factors. Individuals undergoing weight-loss injections often have excessively high expectations regarding body weight. When outcomes fall short of expectations or a plateau phase occurs, they are prone to frustration. Additionally, the gastrointestinal side effects of the medications themselves—such as nausea, vomiting, and fatigue—can further exacerbate physical discomfort, thereby impairing mood.
Is teripalide safer?
Based on available data, reports of emotional-related adverse effects associated with teripalide are indeed fewer than those with semaglutide. A pharmacovigilance analysis conducted in 2024 revealed that among all reported adverse mental effects of GLP-1 agents, semaglutide accounted for 50%, while teripalide accounted for only 3.9%.
This may be attributed to the protective effect of the GIP component in tiramprost, or possibly to its short market availability and limited patient population. Regardless, if significant mood depression occurs with semaglutide use, a medication switch should be discussed with a physician.
Is teripalide safer?
Based on available data, reports of emotional-related adverse effects associated with teripalide are indeed fewer than those with semaglutide. A pharmacovigilance analysis conducted in 2024 revealed that among all reported adverse mental effects of GLP-1 agents, semaglutide accounted for 50%, while teripalide accounted for only 3.9%.
This may be attributed to the protective effect of the GIP component in tiramprost, or possibly to its short market availability and limited patient population. Regardless, if significant mood depression occurs with semaglutide use, a medication switch should be discussed with a physician.
Three recommendations for patients preparing to use medications:
First, assess psychological status before medication administration. If you have a history of depression or anxiety disorders, or are currently taking antidepressants, it is essential to inform your physician. Studies indicate that patients receiving concomitant therapy with antidepressants and semaglutide exhibit a depression risk more than four times higher compared to those using other medications.
Second, pay attention to physical signals. If persistent symptoms such as low mood, decreased interest, and sleep disturbances occur for more than two weeks after medication administration, these may indicate adverse drug reactions (ADRs) and require prompt adjustment.
Third, ensure adequate nutrient intake. Even in cases of poor appetite, it is essential to maintain the intake of nutrients such as protein, B vitamins, magnesium, and zinc. Complex vitamins may be supplemented when necessary, as this is crucial for maintaining emotional stability.